West Pharmaceutical Services (WST)
(Real Time Quote from BATS)
$356.55 USD
-0.93 (-0.26%)
Updated May 1, 2024 10:18 AM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
WST 356.55 -0.93(-0.26%)
Will WST be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for WST based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for WST
West Pharmaceutical (WST) Q1 Earnings Beat, HVP Sales Weak
West Pharmaceutical Services (WST) Tops Q1 Earnings and Revenue Estimates
WST: What are Zacks experts saying now?
Zacks Private Portfolio Services
Conmed (CNMD) Surpasses Q1 Earnings and Revenue Estimates
Will West Pharmaceutical (WST) Beat Estimates Again in Its Next Earnings Report?
Is a Beat Likely for West Pharmaceutical (WST) in Q1 Earnings?
Other News for WST
West to Participate in Upcoming Investor Conference
Dividend Champion, Contender, And Challenger Highlights: Week Of April 28
Decoding West Pharmaceutical Services Inc (WST): A Strategic SWOT Insight
ResMed Inc's Meteoric Rise: Unpacking the 12% Surge in Just 3 Months
West Pharmaceutical Services: Strong Q1 Performance and Upbeat FY24 Outlook Bolster Buy Rating